BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,124,489 | -21.7% | 7,224,000 | -19.7% | 0.34% | -25.6% |
| Q1 2023 | $9,099,180 | -28.7% | 9,000,000 | 0.0% | 0.45% | -13.1% |
| Q4 2022 | $12,757,482 | +2436.3% | 9,000,000 | +1700.0% | 0.52% | +2626.3% |
| Q1 2022 | $503,000 | -4.9% | 500,000 | +9900.0% | 0.02% | -17.4% |
| Q4 2021 | $529,000 | -81.0% | 5,000 | -99.8% | 0.02% | -89.9% |
| Q3 2019 | $2,778,000 | -4.0% | 2,800,000 | 0.0% | 0.23% | -7.3% |
| Q2 2019 | $2,895,000 | -78.0% | 2,800,000 | -78.2% | 0.25% | -81.3% |
| Q1 2019 | $13,188,000 | -0.7% | 12,823,000 | -4.0% | 1.32% | +11.5% |
| Q4 2018 | $13,279,000 | +7.2% | 13,363,000 | +15.1% | 1.18% | +36.9% |
| Q3 2018 | $12,391,000 | +113.2% | 11,613,000 | +100.2% | 0.86% | +98.6% |
| Q2 2018 | $5,813,000 | +6.2% | 5,800,000 | 0.0% | 0.43% | +16.0% |
| Q1 2018 | $5,473,000 | -6.0% | 5,800,000 | 0.0% | 0.37% | +2.5% |
| Q4 2017 | $5,820,000 | – | 5,800,000 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |